Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of $51.82 million. The enterprise value is $45.20 million.
Important Dates
The last earnings date was Friday, March 27, 2026, after market close.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Entera Bio has 45.86 million shares outstanding. The number of shares has increased by 22.69% in one year.
| Current Share Class | 45.86M |
| Shares Outstanding | 45.86M |
| Shares Change (YoY) | +22.69% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 2.69% |
| Owned by Institutions (%) | 12.39% |
| Float | 31.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,233.78 |
| Forward PS | n/a |
| PB Ratio | 3.98 |
| P/TBV Ratio | 3.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,076.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.94, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.94 |
| Quick Ratio | 3.23 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -108.01% and return on invested capital (ROIC) is -65.68%.
| Return on Equity (ROE) | -108.01% |
| Return on Assets (ROA) | -56.78% |
| Return on Invested Capital (ROIC) | -65.68% |
| Return on Capital Employed (ROCE) | -83.60% |
| Weighted Average Cost of Capital (WACC) | 12.28% |
| Revenue Per Employee | $1,909 |
| Profits Per Employee | -$519,955 |
| Employee Count | 22 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.74% in the last 52 weeks. The beta is 1.48, so Entera Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -37.74% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 42.81 |
| Average Volume (20 Days) | 169,493 |
Short Selling Information
The latest short interest is 137,789, so 0.30% of the outstanding shares have been sold short.
| Short Interest | 137,789 |
| Short Previous Month | 124,213 |
| Short % of Shares Out | 0.30% |
| Short % of Float | 0.44% |
| Short Ratio (days to cover) | 1.42 |
Income Statement
In the last 12 months, Entera Bio had revenue of $42,000 and -$11.44 million in losses. Loss per share was -$0.25.
| Revenue | 42,000 |
| Gross Profit | n/a |
| Operating Income | -11.53M |
| Pretax Income | -11.44M |
| Net Income | -11.44M |
| EBITDA | -11.50M |
| EBIT | -11.53M |
| Loss Per Share | -$0.25 |
Full Income StatementBalance Sheet
The company has $7.11 million in cash and $490,000 in debt, with a net cash position of $6.62 million or $0.14 per share.
| Cash & Cash Equivalents | 7.11M |
| Total Debt | 490,000 |
| Net Cash | 6.62M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 13.10M |
| Book Value Per Share | 0.28 |
| Working Capital | 13.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.37 million and capital expenditures -$107,000, giving a free cash flow of -$7.48 million.
| Operating Cash Flow | -7.37M |
| Capital Expenditures | -107,000 |
| Depreciation & Amortization | 30,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.48M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -27,450.00% |
| Pretax Margin | -27,235.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Entera Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.69% |
| Shareholder Yield | -22.69% |
| Earnings Yield | -22.08% |
| FCF Yield | -14.43% |
Analyst Forecast
The average price target for Entera Bio is $10.00, which is 784.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 784.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
